ISAR — Identification of Seniors At Risk
6-item ED screening tool for older adults (McCusker 1999) predicting 30-day adverse outcomes (functional decline, readmission, institutionalisation, mortality). Score ≥2 triggers comprehensive geriatric assessment.
Score interpretation
→ Standard ED disposition. No additional geriatric input required.
→ Refer to ED-frailty / Older Person's Assessment & Liaison (OPAL) team. Avoid prolonged waits in trolley areas. Review medications (STOPP/START), capacity, falls, social support and discharge planning before leaving ED. Front-door frailty pathways shown to reduce admission and improve outcomes (BGS / RCEM 2024).
Interpretation bands for the ISAR. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.